Core Viewpoint - Shenwei Pharmaceutical (02877) reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a year-on-year decrease of 16.3% [1] Revenue Breakdown - The revenue from injection products decreased by 23.6% to RMB 786 million [1] - The revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - The revenue from granule products decreased by 14.5% to RMB 391 million [1] - The revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - The revenue from other dosage forms decreased by 6.1% to RMB 175 million [1]

Core Viewpoint - The company reported a significant decline in revenue for the nine months ending September 30, 2025, with a total revenue of RMB 2.415 billion, representing a 16.3% decrease compared to the same period in 2024 [1] Revenue Breakdown - Revenue from injection products decreased by 23.6% to RMB 786 million [1] - Revenue from soft capsule products decreased by 13.7% to RMB 337 million [1] - Revenue from granule products decreased by 14.5% to RMB 391 million [1] - Revenue from traditional Chinese medicine formula granules decreased by 11.8% to RMB 726 million [1] - Revenue from other dosage forms decreased by 6.1% to RMB 175 million [1] Product Contribution to Total Revenue - Injection products accounted for approximately 32.5% of total revenue [1] - Soft capsule products accounted for approximately 14.0% of total revenue [1] - Granule products accounted for approximately 16.2% of total revenue [1] - Traditional Chinese medicine formula granules accounted for approximately 30.1% of total revenue [1]